When should dapagliflozin (Farxiga) be discontinued based on estimated glomerular filtration rate (eGFR) and related safety concerns?

When to Stop Farxiga Based on eGFR

Do not stop Farxiga (dapagliflozin) when eGFR falls below initiation thresholds—continue therapy even if eGFR drops below 25 mL/min/1.73 m² until dialysis is initiated, as long as the medication is tolerated. 1, 2

eGFR Thresholds by Indication

For Glycemic Control (Type 2 Diabetes)

• Do not initiate if eGFR <45 mL/min/1.73 m² (ineffective for glucose lowering at this level) 2
• If already on therapy: Continue for cardiovascular and kidney benefits even as eGFR declines below 45 mL/min/1.73 m² 3, 2

For Heart Failure or Chronic Kidney Disease

• Do not initiate if eGFR <25 mL/min/1.73 m² 2
• If already on therapy: Continue even if eGFR falls below 25 mL/min/1.73 m² until dialysis or transplantation 1, 2

Key Principle: Continue Through eGFR Decline

The KDIGO 2022 guidelines explicitly state that once an SGLT2i is initiated, it is reasonable to continue even if eGFR falls below 20 mL/min/1.73 m² unless not tolerated or kidney replacement therapy is initiated 1. This recommendation is supported by the DAPA-CKD and DELIVER trials, where patients who experienced eGFR decline to <25 mL/min/1.73 m² while on dapagliflozin had:

• Lower risk of primary cardiovascular outcomes (HR 0.53) compared to placebo 4
• No excess safety events despite deteriorating kidney function 4
• Similar rates of drug discontinuation between treatment groups 4

Managing the Initial eGFR "Dip"

A reversible decrease in eGFR with SGLT2i initiation is expected and is NOT an indication to discontinue therapy 1. This initial dip:

• Averages 3-4 mL/min/1.73 m² within the first 2 weeks 5
• Occurs in approximately 38% of patients (>10% decline) 5
• Is associated with better long-term outcomes, not worse 5
• Should not trigger discontinuation unless accompanied by acute illness or volume depletion 1

Absolute Reasons to Stop Farxiga

Discontinue dapagliflozin only in these specific situations:

1. Dialysis or kidney transplantation initiated 2
2. Intolerance (persistent side effects despite management) 1
3. Ketoacidosis (evaluate and treat; withhold during acute episode) 2
4. Perioperative period: Withhold ≥3 days before major surgery or prolonged fasting 2
5. Critical medical illness with prolonged fasting or risk of ketosis 1
6. Severe volume depletion unresponsive to diuretic adjustment 1

Common Pitfalls to Avoid

Do not stop dapagliflozin for:

• Acute eGFR decline of 10-15% after initiation (this is hemodynamic and protective) 1, 5
• eGFR falling below the initiation threshold while on therapy 1, 2
• Mild hyperkalemia (manage medically first) 1
• Temporary illness (withhold temporarily, then restart) 1

The FDA label explicitly states that patients enrolled in DAPA-CKD and DELIVER trials were not required to discontinue therapy if eGFR fell below 25 mL/min/1.73 m² or if dialysis was initiated 2. This reflects the cardiovascular and mortality benefits that persist independent of glucose-lowering effects at low eGFR 6.

Practical Algorithm

1. Patient on dapagliflozin with declining eGFR:

   • Check for acute illness, volume depletion, or nephrotoxic medications
   • If none present → Continue dapagliflozin
   • If acute issue → Temporarily withhold, address cause, restart when stable

2. eGFR drops below initiation threshold:

   • Continue therapy for cardiovascular/kidney protection 1, 2
   • Monitor volume status and electrolytes more frequently

3. eGFR <25 mL/min/1.73 m²:

   • Continue until dialysis unless not tolerated 1, 2
   • Counsel patient on sick-day management 1

4. Dialysis initiated:

   • Discontinue dapagliflozin 2

The evidence strongly supports continuation through progressive kidney disease, as the cardiovascular and mortality benefits persist even when glucose-lowering effects diminish 4, 6.